Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;19(4):223-235.
doi: 10.1007/s11897-022-00557-y. Epub 2022 May 28.

Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria

Bethany Roehm  1 , Meredith McAdams  2 , S Susan Hedayati  2
Affiliations
Review

Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria

Bethany Roehm et al. Curr Heart Fail Rep. 2022 Aug.

Abstract

Purpose: Kidney disease is a common finding in patients with heart failure and can significantly impact treatment decisions and outcomes. Abnormal kidney function is currently determined in clinical practice using filtration markers in the blood to estimate glomerular filtration rate, but the manifestations of kidney disease in the setting of heart failure are much more complex than this. In this manuscript, we review novel biomarkers that may provide a more well-rounded assessment of kidney disease in patients with heart failure.

Recent findings: Galectin-3, ST2, FGF-23, suPAR, miRNA, GDF-15, and NAG may be prognostic of kidney disease progression. L-FABP and suPAR may help predict acute kidney injury (AKI). ST2 and NAG may be helpful in diuretic resistance. Several biomarkers may be useful in determining prognosis of long-term kidney disease progression, prediction of AKI, and development of diuretic resistance. Further research into the mechanisms of kidney disease in heart failure utilizing many of these biomarkers may lead to the identification of therapeutic targets.

Keywords: Biomarkers; Cardiorenal; Heart failure; Kidney disease; Kidney function.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Bethany Roehm, Meredith McAdams, and S. Susan Hedayati declare that they have no conflict of interest.

References

    1. McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new chronic kidney disease-epidemiology collaboration group formula. Circ Heart Fail. 2012;5(3):309–14. - PubMed
    1. Levin A, Stevens P, Bilous R, Coresh J, De Francisco A, De Jong P, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 3(1):1–150.
    1. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31. - PubMed
    1. Ammirati E, Oliva F, Cannata A, Contri R, Colombo T, Martinelli L, et al. Current indications for heart transplantation and left ventricular assist device: a practical point of view. Eur J Intern Med. 2014;25(5):422–9. - PubMed
    1. Baum N, Dichoso CC, Carlton CE. Blood urea nitrogen and serum creatinine. Physiology and interpretations. Urology. 1975;5(5):583–8. - PubMed

Publication types

Substances

LinkOut - more resources